A Study of the Effect of Lenalidamide on Complex Regional Pain Syndrome Type 1

NCT00166452 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2011-03-23

No results posted yet for this study

Summary

The purpose of this study is to determine if lenalidomide is a safe and effective treatment for complex regional pain syndrome type 1 (CRPS).

Conditions

  • Complex Regional Pain Syndrome, Type 1

Interventions

DRUG

Lenalidamide

Sponsors & Collaborators

  • Elgene Chemical

    collaborator INDUSTRY
  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Keith A Bengtson, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2007-04-30
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00166452 on ClinicalTrials.gov